接受替比夫定抗病毒治疗的HBeAg阳性慢性乙型肝炎患者Treg / Th

StephenW

Medicine (Baltimore). 2017 Jun;96(23):e7064. doi: 10.1097/MD.0000000000007064.
Relationship of Treg/Th17 balance with HBeAg change in HBeAg-positive chronic hepatitis B patients receiving telbivudine antiviral treatment: A longitudinal observational study.Yang X1, Li J, Liu J, Gao M, Zhou L, Lu W.
Author information
1aDepartment of Infection Disease, Baoji People's Hospital. Baoji, Shaanxi Province bTianjin Second People's Hospital, Tianjin Institute of Hepatology. Tianjin, China.

AbstractTelbivudine (LdT) is an orally L-nucleoside with potent and specific antihepatitis B virus (HBV) activity. The higher rate of hepatitis B e antigen (HBeAg) seroconversion of LdT treatment than other anti-HBV agents suggests a potential immunomodulatory effect. The aim of the study was to investigate the changes of regulatory T cell (Treg)/interleukin (IL)-17-producing CD4+T helper (Th17) balance during LdT treatment and to discuss the relationship of Treg/Th17 balance with HBeAg change in HBeAg-positive chronic hepatitis B (CHB) patients receiving LdT antiviral treatment. Twenty-seven HBeAg-positive CHB patients received LdT for 24 weeks and the percentages of Tregs and cells (Th17 cells) in peripheral blood as well as the serum TGF-β1 and IL-17 levels in these patients were longitudinally analyzed. We found that the frequencies of Tregs and Th17 cells in peripheral blood as well as the serum TGF-β1 and IL-17 levels increased significantly in CHB patients compared with healthy controls. During the LdT treatment, the Tregs frequency and TGF-β1 level tended to decrease, and Th17 cells frequency and IL-17 level showed a reverse "V"-type change. The frequency of Tregs and the ratio of Treg/Th17 were significantly lower in the HBeAg loss group than those in the HBeAg no-loss group at the baseline. More important, the Tregs frequency and TGF-β1 level were both positively correlated with HBeAg level during the LdT treatment for 24 weeks. Our data suggest that the lower Tregs frequency and Treg/Th17 ratio at the baseline of LdT treatment, the more likely to get the HBeAg loss. HBeAg negative can be predicted using changes in Tregs frequency and TGF-β1 level during LdT treatment in CHB patients. Maybe we could provide the immunology marker for exploring the mechanism of the higher HBeAg seroconversion rate of LdT therapy.


PMID:28591041DOI:10.1097/MD.0000000000007064

StephenW

医学（巴尔的摩）。 2017年6月; 96（23）：e7064。 doi：10.1097 / MD.0000000000007064。
接受替比夫定抗病毒治疗的HBeAg阳性慢性乙型肝炎患者Treg / Th17平衡与HBeAg变化的关系：纵向观察性研究。
杨X1，李J，刘J，高M，周璐，卢伟
作者信息

1
    宝鸡人民医院感染病科。陕西宝鸡b天津市第二人民医院天津市肝病研究所。天津，中国。

抽象

特比夫定（LdT）是具有强效和特异性乙型肝炎病毒（HBV）活性的口服L-核苷。乙型肝炎e抗原（HBeAg）血清学转换比其他抗HBV药物更高的比率表明潜在的免疫调节作用。本研究的目的是调查LdT治疗期间调节性T细胞（Treg）/白细胞介素（IL）-17产生的CD4 + T辅助细胞（Th17）平衡的变化，并讨论Treg / Th17平衡与HBeAg变化的关系在接受LdT抗病毒治疗的HBeAg阳性慢性乙型肝炎（CHB）患者中。 27例HBeAg阳性CHB患者接受LdT 24周，外周血中Treg和细胞（Th17细胞）的百分比以及这些患者的血清TGF-β1和IL-17水平进行纵向分析。我们发现与健康对照相比，CHB患者的外周血Treg和Th17细胞频率以及血清TGF-β1和IL-17水平显着升高。在LdT治疗期间，Tregs频率和TGF-β1水平趋于降低，Th17细胞频率和IL-17水平呈现反向“V”型变化。 HBeAg损失组Treg和Treg / Th17的比例明显低于HBeAg无损组。更重要的是，Tregs频率和TGF-β1水平与LdT治疗24周时的HBeAg水平呈正相关。我们的数据表明，在LdT治疗的基线下，Tregs频率和Treg / Th17比值越低，获得HBeAg损失的可能性越大。 HBeAg阴性可以使用CHB患者LdT治疗期间Tregs频率和TGF-β1水平的变化进行预测。也许我们可以提供免疫学标记来探索更高的HBeAg血清学转换率的LdT治疗的机制。

结论：
    28591041
DOI：
    10.1097 / MD.0000000000007064

StephenW

http://journals.lww.com/md-journ ... _with_HBeAg.17.aspx